Science Media Center researchers have lately developed a fast-acting antidepressant from the party drug ketamine. According to Allan Young from the Science Media Center, the classic antidepressants take a prolonged period of time to work whereas the new drug can help get things done faster. The derivative has been named “Esketamine” and it is made using one of the components of ketamine. The drug is now made available in the IV form and a nasal spray form in the US market. The drug is available only by prescription and not loosely sold. The FDA had given the current new drug a green signal in March itself.
The UK health regulators and European have decided to start marketing the drug by the end of fall or by next March while the National Institute for Health and Care Excellence is yet to announce its decision. Likewise, the Institute for Health and Care Excellence still has to take a decision. Researchers have proved that Esketamine can perk up patients’ conditions radically that too within a few days or hours whereas the traditional antidepressants would take weeks. The pharmacology and functionality of the new drug are quite different from the traditional version.
President Donald Trump has publicized his keenness in putting the anti-depressant nasal spray which is an imitative of ketamine on a fast track plus has ordered the Department of Veterans Affairs or VA to help speed up the process within a short timeframe. Similarly, Johnson & Johnson (J&J) has also developed an intravenous drug, Spravato, possessing the same effect. It has been estimated that Spravato could gross $600 Million for the company by the end of 2022. And it has been found that during the trials the VA and J&J’s relationship deepened such that they have joined forces to combat suicide. The new clinical trial processes are also being undertaken so as to access the latest development that can help improve the treatment techniques.